ScholarIQanswers from OpenAlex & ORCID
Masafumi Ikeda
ResearcherPublications, citations & collaboration network
Masafumi Ikeda is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Masafumi Ikeda have?
ScholarIQindexed works
Masafumi Ikeda has 1,019 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Masafumi Ikeda have?
ScholarIQcitation count
Masafumi Ikeda has 35,530 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Masafumi Ikeda?
ScholarIQh-index
Masafumi Ikeda has an h-index of 80 in OpenAlex.
What is the i10-index of Masafumi Ikeda?
ScholarIQi10-index
Masafumi Ikeda has an i10-index of 310 in OpenAlex.
What is the ORCID of Masafumi Ikeda?
ScholarIQorcid
The ORCID for Masafumi Ikeda is on the source record.
What is the OpenAlex record for Masafumi Ikeda?
ScholarIQopenalex
The OpenAlex for Masafumi Ikeda is on the source record.
What are the most-cited papers on Masafumi Ikeda?
ScholarIQmost cited works
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, T Shimamura, Masayuki Sho, Masayuki Kitano, Ann‐Lii Cheng, Kazuhiro Mizumoto, Jen‐Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Satō, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P. Hack, Jessica Spahn, Bo Liu, Heba Abdullah, Yulei Wang, Aiwu Ruth He, Kyung-Hun Lee, Y-J. Bang, Johanna C. Bendell, Yee Chao, J-S Chen, Hyun Cheol Chung, S. Lindsey Davis, Atul Dev, Edward Gane, Ben George, Aiwu Ruth He, Howard S. Höchster, C-H Hsu, Masafumi Ikeda, Jes Chauviere Lee, M. Lee, Amit Mahipal, Gulam A. Manji, Manabu Morimoto, Kazushi Numata, Michael J. Pishvaian, Shukui Qin, David P. Ryan, B-Y Ryoo, Naoki Sasahira, Stacey Stein, John H. Strickler, N. C. Tebbutt
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, В. В. Бредер, Hiromitsu Kumada, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Simone I. Strasser, Alexander Thompson, Aflah Roohullah, William Sievert, Vladimir Andelkovic, Jennifer J. Knox, Janine M. Davies, Jamil Asselah, Mayur Brahmania, Habeeb Majeed, Luis J. Villanueva-Rivera, Patricio Yañez Weber, Marcelo Garrido, Gonzalo Pizarro, Nicolás Yáñez, Ruocai Xu, Shuangyan Ou, Zhenggang Ren, Hongming Pan, Zhiqiang Meng, Kangsheng Gu, Xi Chen, Tao Zhang, Chunyi Hao, Peiguo Cao, Yabing Guo, Shukui Qin, Juxiang Xiao, Weijia Fang, Xin Wang, Yuxian Bai, Xiaoming Chen, Dong Yan, Hong Zhao, Jieer Ying, Carlos Bonilla, Olga Urrego, Ángela R. Zambrano, Mauricio Lema, Juan Carlos Restrepo, Andrés F. Cardona, Sandra Franco Millan, Madiedo Oscar, Víctor Ramos, Philippe Merle, Samuel Lesourd, Julien Edeline, Jean–Pierre Bronowicki, Marc Bourlière, Stéphane Cattan, Mohamed Bouattour, Laurent Mineur, Hélène Regnault, Barbara Dauvois, Kornelius Schulze, Gunnar Folprecht, Andreas Geier, Oliver Waidmann, Fabian Finkelmeier, Marino Venerito, Marie‐Luise Berres, Thomas Berg, Christian M. Lange, Hartmut Schmidt, Dirk Waldschmidt, Michael Bitzer, Ray McDermott, Austin G. Duffy, Gianluca Masi, Vittorina Zagonel, Giuseppe Tonini, Fabio Piscaglia, Stefania Gori, Mimma Rizzo, Elisa Biscaldi
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda, Hideaki Bando, Ken Kato, Chigusa Morizane, Taito Esaki, Yoshito Komatsu, Yasuyuki Kawamoto, Naoki Takahashi, Makoto Ueno, Yoshinori Kagawa, Tomohiro Nishina, Takeshi Kato, Yoshiyuki Yamamoto, Junji Furuse, Tadamichi Denda, Hisato Kawakami, Eiji Oki, Takako Eguchi Nakajima, Naohiro Nishida, Kensei Yamaguchi, Hisateru Yasui, Masahiro Goto, Nobuhisa Matsuhashi, Koushiro Ohtsubo, Kentaro Yamazaki, Akihito Tsuji, Wataru Okamoto, Katsuya Tsuchihara, Takeharu Yamanaka, Miki Izumi, Yasutoshi Sakamoto, Hiroko Ichiki, Masayuki Hata, Riu Yamashita, Atsushi Ohtsu, Justin I. Odegaard, Takayuki Yoshino
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Hiroshi Katayama, Makoto Ueno, Masafumi Ikeda, Masato Ozaka, Naohiro Okano, Kazuya Sugimori, Akira Fukutomi, Hiroki Hara, Nobumasa Mizuno, Hiroaki Yanagimoto, Keita Wada, Kazutoshi Tobimatsu, Kei Yane, Shoji Nakamori, Hiroyuki Yamaguchi, Akinori Asagi, Seigo Yukisawa, Yasushi Kojima, Ken Kawabe, Yasuyuki Kawamoto, Rie Sugimoto, Tomohisa Iwai, Kazuyoshi Nakamura, Hiroyoshi Miyakawa, Tatsuya Yamashita, A. Hosokawa, Tatsuya Ioka, Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse